Early evaluation of subclinical cardiotoxicity in HER2-positive breast cancer patients with low-moderate cardiovascular risk using MRI

This study explored the early cardiac changes in HER2-positive patients treated with HER2-targeted or anthracycline therapy through cardiac MRI. The results showed frequent signs of subclinical cardiotoxicity after short-term anti-cancer therapy, despite with low-moderate cardiovascular risk. T1 mapping showed the capability for early detection of pathological myocardial changes before cardiac contractile dysfunction. In HER2-positive breast cancer patients, cardiotoxicity surveillance is important and should be carefully done even with low-moderate cardiovascular risk, especially for those received anthracycline-based therapy.